Ascendis’s Yorvipath Approved By FDA For Hypoparathyroidism But US Launch Delayed

Yorvipath Will Fill Gap Left By Takeda’s Natpara

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.